CG
MYGN icon

Cutler Group’s Myriad Genetics MYGN Stock Holding History

Cutler Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,100
Closed -$36K – 4602
2019
Q1 		$36K Buy
+1,100
New +$33.5K ﹤0.01% 1637
2017
Q4 		– Sell
-1,891
Closed -$63.8K – 5547
2017
Q3 		$68K Sell
1,891
-9,514
-83% -$271K ﹤0.01% 1969
2017
Q2 		$294K Buy
11,405
+10,863
+2,004% +$231K 0.01% 1003
2017
Q1 		$10K Sell
542
-1,400
-72% -$24.8K ﹤0.01% 4038
2016
Q4 		$32K Sell
1,942
-7,480
-79% -$135K ﹤0.01% 2991
2016
Q3 		$193K Buy
+9,422
New +$239K 0.01% 1249
2016
Q1 		– Sell
-310
Closed -$11.7K – 6932
2015
Q4 		$13K Buy
+310
New +$13.1K ﹤0.01% 3864

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cutler Group's MYGN Position: Q2 2019 in Review

Cutler Group sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 1,100 shares — an estimated $36K sold.

Cutler Group first reported a position in MYGN in Q4 2015 and held it in 7 quarters. The position peaked at $294K in Q2 2017. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

  • Cutler Group reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
  • Cutler Group sold 1,100 Myriad Genetics shares in Q2 2019, an estimated $36K.
  • Cutler Group first reported a position in Myriad Genetics in Q4 2015 and held it in 7 quarters.
  • Cutler Group's Myriad Genetics position peaked at $294K in Q2 2017.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Cutler Group's 13F filing for Q2 2019, filed 9 Aug 2019.